These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 22462553

  • 21. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
    Sawafuji K, Miyakawa Y, Weisberg E, Griffin JD, Ikeda Y, Kizaki M.
    Leuk Lymphoma; 2003 Nov; 44(11):1987-96. PubMed ID: 14738154
    [Abstract] [Full Text] [Related]

  • 22. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
    Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Plattner R.
    PLoS One; 2013 Nov; 8(1):e55509. PubMed ID: 23383209
    [Abstract] [Full Text] [Related]

  • 23. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K.
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [Abstract] [Full Text] [Related]

  • 24. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
    Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, de Jong S, Kruyt FA.
    Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
    [Abstract] [Full Text] [Related]

  • 25. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells.
    Kohmura K, Miyakawa Y, Kawai Y, Ikeda Y, Kizaki M.
    J Cell Physiol; 2004 Mar; 198(3):370-6. PubMed ID: 14755542
    [Abstract] [Full Text] [Related]

  • 26. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C, Krystal G, Dent P, Grant S.
    Clin Cancer Res; 2002 Sep; 8(9):2976-84. PubMed ID: 12231544
    [Abstract] [Full Text] [Related]

  • 27. MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine.
    Sun G, Jin S, Baskaran R.
    Exp Cell Res; 2009 Nov 01; 315(18):3163-75. PubMed ID: 19766113
    [Abstract] [Full Text] [Related]

  • 28. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
    Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ.
    Blood; 2006 Nov 15; 108(10):3450-7. PubMed ID: 16741250
    [Abstract] [Full Text] [Related]

  • 29. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 30. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S.
    Clin Cancer Res; 2013 Jan 15; 19(2):404-14. PubMed ID: 23204129
    [Abstract] [Full Text] [Related]

  • 31. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
    Yu C, Dai Y, Dent P, Grant S.
    Cancer Biol Ther; 2002 Jan 15; 1(6):674-82. PubMed ID: 12642693
    [Abstract] [Full Text] [Related]

  • 32. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
    Dong Y, Xiong M, Duan L, Liu Z, Niu T, Luo Y, Wu X, Xu C, Lu C.
    Apoptosis; 2014 Aug 15; 19(8):1281-92. PubMed ID: 24830786
    [Abstract] [Full Text] [Related]

  • 33. Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.
    Wilson MK, McWhirter SM, Amin RH, Huang D, Schlissel MS.
    Mol Cells; 2010 Apr 15; 29(4):333-41. PubMed ID: 20213318
    [Abstract] [Full Text] [Related]

  • 34. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Biochem Pharmacol; 2004 Jul 01; 68(1):85-93. PubMed ID: 15183120
    [Abstract] [Full Text] [Related]

  • 35. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.
    Blood; 2005 Apr 15; 105(8):3303-11. PubMed ID: 15626746
    [Abstract] [Full Text] [Related]

  • 36. Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells.
    Chang SP, Shen SC, Lee WR, Yang LL, Chen YC.
    J Dermatol Sci; 2011 Jun 15; 62(3):183-91. PubMed ID: 21482077
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde.
    Kim HB, Kim MJ, Kim DY, Lee JW, Bae JH, Kim DW, Kang CD, Kim SH.
    Mol Cancer; 2011 Apr 25; 10():46. PubMed ID: 21513580
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.